Deal for Hep B was very definitely completed before the board...

Deal for Hep B was very definitely completed before the board chose to announce the cessation of the TT-034 trial. No company would abandon such a significant investment of resources/time/reputation/market risk in a proof-of-concept trial without a much much better offer in the other hand. Big pharma was there all along. Announcement imminent.

J8: No capital raising at these prices as it would jeopardize US Nasaq listing. Sabby & Co will have first opportunity to soak up cheap shares by buying on market pushing price to circa .50 cents + before momentum builds with well timed (and preconceived) announcements. This was the carrot.

gwil: CEO is currently being groomed by all stakeholders to take the helm. The company made this clear when they said his recruitment is "progressing well''. This is the stick.

Its an oldie but a goody - distressed company aloud to fall to give new (and old) shareholders a longer runway of price appreciation before BOOM announcement sends it into the stratosphere (again) but this time with the coveted Hep B prize.

Good luck to all holders.